![]() ![]() PubMedīrastianos PK, Kim AE, Wang N, Lee EQ, Ligibel J, Cohen JV, Chukwueke UN, Mahar M, Oh K, White MD, Shih HA, Forst D, Gainor JF, Heist RS, Gerstner ER, Batchelor TT, Lawrence D, Ryan DP, Iafrate AJ, Giobbie-Hurder A, Santagata S, Carter SL, Cahill DP, Sullivan RJ. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. Naik GS, Buchbinder EI, Cohen JV, Manos MP, Johnson AEW, Bowling P, Aizer AA, Schoenfeld JD, Lawrence DP, Haq R, Hodi FS, Sullivan RJ, Ott PA. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. ![]() PubMedĭurbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL. Dual hereditary and immune-mediated neuromuscular diagnoses after cancer immunotherapy. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Rejection of benign melanocytic nevi by nevus-resident CD4 T cells. ![]() Schiferle EB, Cheon SY, Ham S, Son HG, Messerschmidt JL, Lawrence DP, Cohen JV, Flaherty KT, Moon JJ, Lian CG, Sullivan RJ, Demehri S. Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. PubMedīai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. Here are some pages which outline the history of Lawrence, a planned industrial city dating back to 1845.Ott PA, Nazzaro M, Pfaff KL, Gjini E, Felt KD, Wolff JO, Buchbinder EI, Haq R, Sullivan RJ, Lawrence DP, McDermott DF, Severgnini M, Giobbie-Hurder A, Rodig SJ, Stephen Hodi F. I: “The influx of Boston capital created a mill city almost overnight and for nearly a mile on both banks of the stately Merrimack there tower the red brick walls of manufacturing establishment.” Historian, Orra Stone, said this about the city in History of Massachusetts Industries: Their Inception, Growth, and Success - Vol. In so doing, key players - Daniel Saunders, Sr., John Nesmith, Edmund Bartlett, and Samuel Lawrence - took steps to secure ample capital and petitioned the state to build a dam and to create and sell water power between Lowell and Lawrence. They sought to replicate their success ten miles downriver in Lawrence at the confluence of the Merrimack, Shawsheen, and Spicket rivers. In 1843 he, along with other visionaries, formed the Merrimack Water Power Association and accelerated land purchases along the Merrimack, including a total of seven and a half square miles from Methuen and Andover, which would eventually become the city of Lawrence.īoston-based investors, the Boston Associates, had already developed nearby Lowell as one of the first planned industrial cities. During the 1830s, Daniel Saunders, called the Founder of Lawrence, purchased strips of land on either side of the Merrimack River to gain control of waterpower rights.
0 Comments
Leave a Reply. |